S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
NASDAQ:RYTM

Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News

$17.11
+0.21 (+1.24%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$16.25
$17.15
50-Day Range
$16.88
$31.14
52-Week Range
$3.04
$34.99
Volume
624,360 shs
Average Volume
627,366 shs
Market Capitalization
$970.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Rhythm Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
110.4% Upside
$36.00 Price Target
Short Interest
Bearish
15.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
0.68mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$172,045 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.95) to ($2.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

308th out of 995 stocks

Pharmaceutical Preparations Industry

134th out of 482 stocks


RYTM stock logo

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Stock News Headlines

Geek Review: Rhythm Sprout
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
The Best Rhythm VR Games
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Company Calendar

Last Earnings
3/01/2023
Today
3/27/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RYTM
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+110.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-181,120,000.00
Net Margins
-766.22%
Pretax Margin
-766.22%

Debt

Sales & Book Value

Annual Sales
$23.64 million
Book Value
$4.69 per share

Miscellaneous

Free Float
54,592,000
Market Cap
$970.99 million
Optionable
Optionable
Beta
1.82

Key Executives

  • David P. Meeker
    Chairman, President & Chief Executive Officer
  • Hunter C. Smith
    Chief Financial Officer & Treasurer
  • Brieana Buckley
    Vice President-Medical Affairs
  • Joseph Shulman
    Chief Technical Officer
  • Yann Mazabraud
    Executive Vice President & Head-International













RYTM Stock - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings
or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price forecast for 2023?

6 analysts have issued 12 month price targets for Rhythm Pharmaceuticals' shares. Their RYTM share price forecasts range from $20.00 to $56.00. On average, they expect the company's share price to reach $36.00 in the next year. This suggests a possible upside of 110.4% from the stock's current price.
View analysts price targets for RYTM
or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2023?

Rhythm Pharmaceuticals' stock was trading at $29.12 at the beginning of the year. Since then, RYTM stock has decreased by 41.2% and is now trading at $17.11.
View the best growth stocks for 2023 here
.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our RYTM earnings forecast
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings results on Wednesday, March, 1st. The company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.82) by $0.07. The company earned $8.80 million during the quarter, compared to analyst estimates of $7.16 million. Rhythm Pharmaceuticals had a negative net margin of 766.22% and a negative trailing twelve-month return on equity of 74.17%. Rhythm Pharmaceuticals's quarterly revenue was up 388.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.85) earnings per share.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.79%), NEA Management Company LLC (8.71%), Alkeon Capital Management LLC (3.97%), Opaleye Management Inc. (1.30%), Assenagon Asset Management S.A. (0.82%) and Geode Capital Management LLC (0.81%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $17.11.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $970.99 million and generates $23.64 million in revenue each year. The company earns $-181,120,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

The company employs 140 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.

This page (NASDAQ:RYTM) was last updated on 3/28/2023 by MarketBeat.com Staff